250 related articles for article (PubMed ID: 33727237)
1. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.
Rivellese F; Manou-Stathopoulou S; Mauro D; Goldmann K; Pyne D; Rajakariar R; Gordon P; Schafer P; Bombardieri M; Pitzalis C; Lewis MJ
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33727237
[TBL] [Abstract][Full Text] [Related]
2. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
[TBL] [Abstract][Full Text] [Related]
3. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.
Nakayama Y; Kosek J; Capone L; Hur EM; Schafer PH; Ringheim GE
J Immunol; 2017 Oct; 199(7):2388-2407. PubMed ID: 28848067
[TBL] [Abstract][Full Text] [Related]
4. Interferon
Akita K; Yasaka K; Shirai T; Ishii T; Harigae H; Fujii H
Front Immunol; 2020; 11():498703. PubMed ID: 33633721
[TBL] [Abstract][Full Text] [Related]
5. Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE; Vollenhoven RV; Dörner T; Werth VP; Merrill JT; Furie R; Petronijevic M; Velasco Zamora B; Majdan M; Irazoque-Palazuelos F; Terbrueggen R; Delev N; Weiswasser M; Korish S; Stern M; Hersey S; Ye Y; Gaudy A; Liu Z; Gagnon R; Tang S; Schafer PH
Ann Rheum Dis; 2022 Apr; 81(8):1136-42. PubMed ID: 35477518
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Reprogramming Commits Differentiation of Human CD27
Torigoe M; Iwata S; Nakayamada S; Sakata K; Zhang M; Hajime M; Miyazaki Y; Narisawa M; Ishii K; Shibata H; Tanaka Y
J Immunol; 2017 Jul; 199(2):425-434. PubMed ID: 28626065
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT; Werth VP; Furie R; van Vollenhoven R; Dörner T; Petronijevic M; Velasco J; Majdan M; Irazoque-Palazuelos F; Weiswasser M; Korish S; Ye Y; Gaudy A; Schafer PH; Liu Z; Agafonova N; Delev N
N Engl J Med; 2022 Mar; 386(11):1034-1045. PubMed ID: 35294813
[TBL] [Abstract][Full Text] [Related]
8. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice.
Sun J; Matthias G; Mihatsch MJ; Georgopoulos K; Matthias P
J Immunol; 2003 Feb; 170(4):1699-706. PubMed ID: 12574333
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
10. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
Furie RA; Hough DR; Gaudy A; Ye Y; Korish S; Delev N; Weiswasser M; Zhan X; Schafer PH; Werth VP
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35169036
[TBL] [Abstract][Full Text] [Related]
11. [THE IDENTIFICATION OF SUB-POPULATIONS OF B-LYMPHOCYTES OF PERIPHERAL BLOOD USING TECHNIQUE OF FLOW CYTOFLUOROMETRY IN HEALTHY INDIVIDUALS AND PATIENTS WITH RHEUMATOID DISEASES].
Suponitskaia EV; Aleksankin AP; Aleksandrova EN; Avdeeva AS; Panafidina TA; Verijnikova JG; Nasonov EL
Klin Lab Diagn; 2015 Jun; 60(6):30-3. PubMed ID: 26466448
[TBL] [Abstract][Full Text] [Related]
12. CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro.
Néron S; Boire G; Dussault N; Racine C; de Brum-Fernandes AJ; Côté S; Jacques A
Arch Immunol Ther Exp (Warsz); 2009; 57(6):447-58. PubMed ID: 19866343
[TBL] [Abstract][Full Text] [Related]
13. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.
Fleischer SJ; Giesecke C; Mei HE; Lipsky PE; Daridon C; Dörner T
Arthritis Rheumatol; 2014 Dec; 66(12):3424-35. PubMed ID: 25156507
[TBL] [Abstract][Full Text] [Related]
14. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus.
Shirota Y; Yarboro C; Fischer R; Pham TH; Lipsky P; Illei GG
Ann Rheum Dis; 2013 Jan; 72(1):118-28. PubMed ID: 22858586
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Aiolos in Peripheral Blood Mononuclear Cell Subsets from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Cai X; Liu X; Du S; Xu X; Liu A; Ge X; Qiao Y; Jiang Y
Biochem Genet; 2016 Feb; 54(1):73-82. PubMed ID: 26546109
[TBL] [Abstract][Full Text] [Related]
17. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus.
Odendahl M; Keitzer R; Wahn U; Hiepe F; Radbruch A; Dörner T; Bunikowski R
Ann Rheum Dis; 2003 Sep; 62(9):851-8. PubMed ID: 12922958
[TBL] [Abstract][Full Text] [Related]
18. Plasmablast-like Phenotype Among Antigen-Experienced CXCR5-CD19
Szelinski F; Stefanski AL; Schrezenmeier E; Rincon-Arevalo H; Wiedemann A; Reiter K; Ritter J; Lettau M; Dang VD; Fuchs S; Frei AP; Alexander T; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Sep; 74(9):1556-1568. PubMed ID: 35507291
[TBL] [Abstract][Full Text] [Related]
19. STAT3 phosphorylation mediates the stimulatory effects of interferon alpha on B cell differentiation and activation in SLE.
De Groof A; Ducreux J; Aleva F; Long AJ; Ferster A; van der Ven A; van de Veerdonk F; Houssiau FA; Lauwerys BR
Rheumatology (Oxford); 2020 Mar; 59(3):668-677. PubMed ID: 31504941
[TBL] [Abstract][Full Text] [Related]
20. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus.
Iwata S; Yamaoka K; Niiro H; Jabbarzadeh-Tabrizi S; Wang SP; Kondo M; Yoshikawa M; Akashi K; Tanaka Y
Lupus; 2015 Jun; 24(7):695-704. PubMed ID: 25432781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
